Market Overview

Selventa to Participate in a High Profile Panel on Companion Diagnostics at BIO-Europe 2012

CAMBRIDGE, Mass.--(BUSINESS WIRE)--

Selventa today announced that the David de Graaf, Selventa's President and Chief Executive Officer, will participate in a high profile panel on companion diagnostics entitled “Reinvigorating pharma pipelines through companion diagnostics” at BIO-Europe 2012, on November 12 at 17:15 in Hamburg, Germany.

De Graaf will be joined by fellow panelists Guy Greiveldinger, Director, BD&L and M&A, Novartis; Bruce Jordan, Senior International Product Manager, Roche Diagnostics; David L. Dolinger, Executive VP, Seegene; and moderator Toby Zaleski, Principal, Base Pair Group. BIO-Europe 2012 is the pre-eminent partnering meeting in the life science industry, attracting more than 3,000 executives who will engage in over 15,000 one-to-one partnering meetings.

De Graaf will also be giving a company presentation to the BIO-Europe delegation on Tuesday, November 13, 2012 at 16:15.

“Participating in this panel provides Selventa with an excellent opportunity to discuss important issues facing the companion diagnostics market. Selventa has a long, successful history with pharma in the development of companion diagnostics, and in the past year alone we have entered into five CDx development deals in the areas of autoimmune and oncology,” said de Graaf.

“We look forward to showing how Selventa's novel Systems Diagnostics approach can produce high-value, multi-analyte diagnostics tests that accurately predict which patient will respond to which drug. Furthermore, we aim to dispel the commonly held belief among many in the industry that CDx are strictly market limiting, when in fact they can act as powerful catalysts for the majority of drug developers and increase value.”

About Selventa

Selventa is pioneering the development of Systems Diagnostics (SysDx™). This novel approach to diagnostic development harnesses a comprehensive range of complex, biological information (genomic, epigenomic, transcriptomic, proteomic, metabolomic, electronic medial records) to generate a clinically relevant dashboard that physicians, patients and researchers can use to make an optimal treatment decision or stratify patient populations.

SysDx tests are enabled by Selventa's “big data” analytics engine that integrates, processes, and analyzes the molecular information from thousands of patients to identify biomarkers linked to disease-driving mechanisms. SysDx tests are differentiated by their ability to capture a holistic picture of a patient's disease and drug-response profile. This is in contrasts to MDx tests that are limited by their focus on a particular class of biological analytes (e.g. genomics-only tests). This superior predictive and prognostic value is required in the diagnosis of complex multi-factorial diseases such as autoimmune disease and cancer.

Selventa is collaborating with pharmaceutical and diagnostic firms in the application of SysDx in personalized healthcare initiatives including companion diagnostic development and patient stratification.

For more information, visit www.selventa.com

For Selventa
Diane H. Song, Ph.D., 617-547-5421 x235
dsong@selventa.com
or
Base Pair Group
Constantine Theodoropulos
constantine[at]basepairgroup.com
www.basepairgroup.com

 

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free